We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pharmexa has entered into an agreement to acquire GemVax AS, a private Norwegian
biotech company focusing on cancer vaccines. The purchase price will be paid
in newly issued Pharmexa shares and by issuance of a convertible debt instrument.
A national coalition led by PhRMA will spend roughly
$30 million through June to develop and promote a program that would help low-income
Americans gain access to the medicines they need.
The overall quality of direct-to-consumer (DTC) advertising has been declining,
according to the head of the FDA's Division of Drug Marketing, Advertising,
and Communications (DDMAC), which last year issued a record number of warning
letters for violations of the agency's ad requirements.
Private biopharmaceutical firm, VasoGenix Pharmaceuticals, has signed a worldwide
agreement with QLT USA Inc. to develop a potentially major new treatment for
congestive heart failure.
Diversa Corporation announced that it has signed an agreement with Cargill Health
and Food Technologies to discover and develop novel enzymes for the cost-effective
production of a proprietary product.
CellCentric, a Cambridge company exploiting a critical area of genetic research,
has won £250,000 funding that has triggered a commercial collaboration
with Babraham Institute.
Reliant Pharmaceuticals, Inc. announced that the term of the promotion agreement
with Novartis for Lescol (fluvastatin sodium) and Lescol XL (fluvastatin sodium
extended-release tablets) will be extended.